Pharmaceuticals, Biotechnology and Life Sciences
Boehringer Ingelheim has announced new data from the pivotal Phase II Effisayil 1 trial, presented at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston.
Temedica GmbH has announced cooperation with Bristol Myers Squibb to develop a digital companion for patients with psoriasis.
DUBLIN–(BUSINESS WIRE)–The “Psoriasis Market and Forecast Analysis to 2025” drug pipelines has been added to ResearchAndMarkets.com’s offering. Psoriasis is a…
Novartis got approval from the China Health Authority NMPA for
Cosentyx, its the first-in-class interleukin-17A inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.
OSS, The Netherlands–(BUSINESS WIRE)–Lead Pharma, a pharmaceutical company developing innovative medicines for the treatment of immunological and oncological indications, today…
ANDERNACH, Germany & BALLERUP, Denmark–(BUSINESS WIRE)–LTS Lohmann Therapie-Systeme AG (LTS), a market leader in transdermal therapeutic systems, and LEO Pharma…
Novartis has had Cosentyx compared against Janssen’s IL-23 Stelara, and it showed superior improvements for psoriasis patients, it said in a statement Tuesday, noting that it was processed and transmitted by West Corporation.
Eli Lilly said Tuesday that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz injection 80 mg/mL to…
Novartis has announced first-of-its-kind long-term data showing that Cosentyx (secukinumab) provided sustained improvements in nail and palmoplantar psoriasis out to…
The Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Novartis’s Cosentyx (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis.